Calamos Advisors LLC Summit Therapeutics Inc. Transaction History
Calamos Advisors LLC
- $18.8 Billion
- Q3 2025
A detailed history of Calamos Advisors LLC transactions in Summit Therapeutics Inc. stock. As of the latest transaction made, Calamos Advisors LLC holds 18,628 shares of SMMT stock, worth $339,774. This represents 0.0% of its overall portfolio holdings.
Number of Shares
18,628
Previous 23,117
19.42%
Holding current value
$339,774
Previous $491,000
21.38%
% of portfolio
0.0%
Previous 0.0%
Shares
5 transactions
Others Institutions Holding SMMT
# of Institutions
266Shares Held
94.2MCall Options Held
4.72MPut Options Held
4.03M-
Baker Bros. Advisors LP New York, NY33.7MShares$615 Million5.7% of portfolio
-
Vanguard Group Inc Valley Forge, PA11.4MShares$208 Million0.0% of portfolio
-
Black Rock Inc. New York, NY7.9MShares$144 Million0.0% of portfolio
-
State Street Corp Boston, MA6.36MShares$116 Million0.0% of portfolio
-
Price T Rowe Associates Inc Baltimore, MD4.54MShares$82.8 Million0.01% of portfolio
About Summit Therapeutics Inc.
- Ticker SMMT
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 201,215,008
- Market Cap $3.67B
- Description
- Summit Therapeutics Inc., a biopharmaceutical company, discovers, develops, and commercializes medicines to treat infectious diseases in the United States and Latin America. It conducts clinical programs focusing on Clostridioides difficile infection (CDI). The company's lead product candidate is ridinilazole, an orally administered small molecu...